Maslov L N, Krylatov A V, Lishmanov A Iu, Solenkova N V, Bogomaz S A
Siberian State Medical University, Tomsk, 634050 Russia.
Eksp Klin Farmakol. 2001 Mar-Apr;64(2):41-4.
The cardioselective KATP channel activator BMS 180448 (3 mg/kg) administered intravenously 15 min before the coronary artery occlusion (10 min) decreased the incidence of ischemic and reperfusion arrhythmias in rats. A similar antiarrhythmic effect was observed when BMS 180448 was infused 2 min before reperfusion. Pretreatment with BMS 180448 also prevented the occurrence of CsCl induced arrhythmias, but but did not affect the incidence of epinephrine induced arrhythmias. On the contrary, BMS 180448 potentiated the arrhythmogenic action of CaCl2. The mechanism of the antiarrhythmic activity of BMS 180448 is discussed.
在冠状动脉闭塞（10分钟）前15分钟静脉注射心脏选择性KATP通道激活剂BMS 180448（3毫克/千克）可降低大鼠缺血和再灌注心律失常的发生率。在再灌注前2分钟输注BMS 180448时观察到类似的抗心律失常作用。BMS 180448预处理也可预防CsCl诱导的心律失常的发生，但不影响肾上腺素诱导的心律失常的发生率。相反，BMS 180448增强了CaCl2的致心律失常作用。文中讨论了BMS 180448抗心律失常活性的机制。
